AR129441A1 - Péptidos y métodos para el tratamiento del dolor - Google Patents

Péptidos y métodos para el tratamiento del dolor

Info

Publication number
AR129441A1
AR129441A1 ARP230101325A ARP230101325A AR129441A1 AR 129441 A1 AR129441 A1 AR 129441A1 AR P230101325 A ARP230101325 A AR P230101325A AR P230101325 A ARP230101325 A AR P230101325A AR 129441 A1 AR129441 A1 AR 129441A1
Authority
AR
Argentina
Prior art keywords
seq
peptide
pain
identity
composition
Prior art date
Application number
ARP230101325A
Other languages
English (en)
Spanish (es)
Inventor
Stphane Gaillard
Abdelaziz Moqrich
Original Assignee
Tafalgie Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tafalgie Therapeutics filed Critical Tafalgie Therapeutics
Publication of AR129441A1 publication Critical patent/AR129441A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP230101325A 2022-05-25 2023-05-24 Péptidos y métodos para el tratamiento del dolor AR129441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22305773 2022-05-25

Publications (1)

Publication Number Publication Date
AR129441A1 true AR129441A1 (es) 2024-08-28

Family

ID=81975215

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101325A AR129441A1 (es) 2022-05-25 2023-05-24 Péptidos y métodos para el tratamiento del dolor

Country Status (12)

Country Link
US (1) US20250213654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4531886A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025519127A (cg-RX-API-DMAC7.html)
KR (1) KR20250017221A (cg-RX-API-DMAC7.html)
CN (1) CN119730868A (cg-RX-API-DMAC7.html)
AR (1) AR129441A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023275937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253053A1 (cg-RX-API-DMAC7.html)
IL (1) IL317048A (cg-RX-API-DMAC7.html)
MX (1) MX2024014419A (cg-RX-API-DMAC7.html)
TW (1) TW202409064A (cg-RX-API-DMAC7.html)
WO (1) WO2023227731A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
CN103382220A (zh) * 2012-05-03 2013-11-06 北京大学 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
MX2024014419A (es) 2024-12-06
IL317048A (en) 2025-01-01
AU2023275937A1 (en) 2024-12-12
KR20250017221A (ko) 2025-02-04
CA3253053A1 (en) 2023-11-30
CN119730868A (zh) 2025-03-28
TW202409064A (zh) 2024-03-01
WO2023227731A1 (en) 2023-11-30
EP4531886A1 (en) 2025-04-09
JP2025519127A (ja) 2025-06-24
US20250213654A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
PE20230301A1 (es) Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
BR112022027096A2 (pt) Composições e métodos relacionados a agentes terapêuticos ativáveis
PE20241187A1 (es) Moleculas de arn
MX2024015050A (es) L-asparaginasa modificada
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
MX2022014082A (es) Secuencias de interleucina (il-2) y usos de las mismas.
AR125379A1 (es) Un fab anti-tslp con estabilidad mejorada
CU24746B1 (es) Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular
PE20231442A1 (es) Proteinas actrii y sus usos
DE69834136D1 (de) Gefrierschutzprotein
AR114722A1 (es) Composiciones de erenumab y usos de las mismas
AR123187A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
McGee et al. Human seminal vesicle-specific antigen during semen liquefaction
AR132053A1 (es) Composiciones para su uso en el tratamiento de clamidia
MX2021011407A (es) Proteinas de dominio ccn recombinantes y proteinas de fusion.
Brunati et al. Isolation and identification of two proto‐oncogene products related to c‐fgr and fyn in a tyrosine‐protein‐kinase fraction of rat spleen
JP2025519127A5 (cg-RX-API-DMAC7.html)
AR129864A1 (es) Péptidos y métodos para uso en tratar el dolor
Neurath et al. The Denaturation of Proteins and its Apparent Reversal. III.
MX2024008759A (es) Peptidos y composicion farmaceutica para el tratamiento de tumores.
DK1296675T3 (da) Sammensætninger baseret på aminosyrer, egnet til behandling af hjertesvigt
Liao et al. Structural characterization of dioscorin, the major tuber protein of yams, by near infrared Raman spectroscopy
WO2024016011A3 (en) Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses
Chijiwa et al. Suppression of severe lesions, myonecrosis and hemorrhage, caused by Protobothrops flavoviridis venom with its serum proteins